Patients with evidence of enteropathy were designated to group one (41 percent celiac disease) and patients without evidence of enteropathy were designated to group two (59 percent non-celiac gluten sensitivity).
Here are four points:
1. Cerebellar ataxia, peripheral neuropathy and encephalopathy were found to be the most common neurological manifestations among all of the patients.
2. A larger percentage of patients in group one had encephalopathy and a greater percentage of patients in group two had neuropathy. However, the neuropathy was more severe in group one.
3. The two groups had similar severity of ataxia and all patients responded to a gluten-free diet.
4. Anti-tissue transglutaminase antibodies were found in 91 percent of patients in group one and 29 percent of patients in group two.
More articles on GI & endoscopy:
GI physician leader to know: Dr. Shivagi Kothari of University of Rochester Medical Center
EndoChoice receives average price target of $19.67: 4 points
URMC GI experts to host advanced endoscopy course for nurses, mid-level providers: 4 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
